PRESTIGE BIOPHARMA LIMITED

All News Prestige BioPharma Limited

Equities

A950210

KR8702070002

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-12 pm EDT			5-day change	1st Jan Change
7,980 ^KRW	-0.50%		-1.48%	-15.82%

2023	Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer	CI
2023	Prestige BioPharma Limited Develops First-In-Class PAUF-detecting Diagnostic Kit	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer	23-03-21	CI
Prestige BioPharma Limited Develops First-In-Class PAUF-detecting Diagnostic Kit	23-03-09	CI
Prestige Biopharma Submits Pre-BLA Type 4 Meeting Request to FDA for Herceptin Biosimilar	22-10-13	CI
Prestige Biologics Co., Ltd. announced that it has received KRW 6.893915 billion in funding from Prestige BioPharma Limited	22-09-04	CI
Prestige Biologics Co., Ltd. announced that it expects to receive KRW 6.893915 billion in funding from Prestige BioPharma Limited	22-08-25	CI
Prestige Biopharma and Intas Pharmaceuticals Announce Partnership to Commercialize Bevacizumab Biosimilar in the Us, Europe, Canada, Mena, Brazil, Mexico, South Africa, Cis and the Sea Countries	22-07-26	CI
US FDA Approves Prestige Biopharma’s IND for Phase 1/2a Trial of First-in-Class Pancreatic Cancer Treatment, PBP1510	22-06-27	CI
Prestige Biopharma Enters MOU with Vaxine for Supply of COVID-19 Vaccine and Co-development of COVID-19/Influenza Combo Vaccine	22-03-29	CI
The Result of the Phase 3 Study for Prestige BioPharma’s Herceptin Biosimilar, HD201(Tuznue®), Published in JAMA Oncology	22-03-11	CI
Prestige BioPharma Limited Announces Preclinical Data of Pancreatic Cancer Treatment, PBP1510, Present in ESMO TAT 2022	22-03-08	CI
Prestige BioPharma Limited Commences Construction of Innovative Discovery Center in Busan, Korea	21-12-19	CI
Prestige BioPharma and Dr. Reddy’s Announce Partnership to Commercialize Trastuzumab Biosimilar in Select Countries in Latin America and Southeast Asia	21-12-08	CI
Prestige BioPharma Limited(KOSE:A950210) added to S&P Global BMI Index	21-09-20	CI
Prestige BioPharma : Institutional Shareholders, Appreciate its High Growth Potential and Invest with a Long-term View	21-08-02	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Stock Market
Equities
A950210 Stock
News Prestige BioPharma Limited

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW